Related Experiment Video
Updated: Jun 28, 2025
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Xinmailong injection on left ventricular remodeling and inflammatory mediators in patients with CHF: a systematic
Xu Han1, Xi Chen1, Yanling Liu2
1Chongqing Changshou Traditional Cinese Medicine Hospital, Chongqing, China.
Insights
Xinmailong injection (XMLI) combined with conventional treatment (CT) significantly improves left ventricular remodeling (LVR) and reduces inflammation in chronic heart failure (CHF) patients, without increasing adverse events.
Area of Science:
- Cardiology
- Pharmacology
- Medical Research
Background:
- Chronic heart failure (CHF) presents significant mortality risks, with left ventricular remodeling (LVR) and inflammation being key progression factors.
- Targeting LVR and inflammation is crucial for managing CHF and improving patient outcomes.
Approach:
- A systematic review and meta-analysis evaluated randomized controlled trials on Xinmailong injection (XMLI) for CHF.
- Data were sourced from eight databases, with quality assessed using the Cochrane bias risk tool.
- Statistical analyses, including sensitivity and publication bias assessments, were performed using Stata 17.0.
Key Points:
- XMLI combined with conventional treatment (CT) significantly improved LVR markers (LVEF, LVEDD, LVESD) and reduced inflammatory mediators (TNF-α, IL-6, IL-18, CRP, hs-CRP) while increasing IL-10.
- The combination therapy enhanced clinical efficacy, reduced BNP and NT-pro BNP levels, and improved the 6-minute walk distance (6-MWD).
- No significant increase in adverse reactions was observed with the combination therapy.
Conclusions:
- Combining XMLI with CT offers superior benefits for LVR and inflammation in CHF patients compared to CT alone.
- This therapeutic approach is safe, with no increased risk of adverse events.
- Caution is advised due to the limited quality of the included studies.
Background:
Chronic heart failure (CHF) is a prevalent and highly challenging cardiovascular disease associated with high mortality rates. The occurrence and progression of CHF are closely linked to left ventricular remodeling (LVR) and inflammation. Addressing LVR and reducing inflammation can significantly slow down the progression of CHF and improve patient prognosis.
Objective:
To evaluate the effects of Xinmailong injection (XMLI) on LVR and inflammatory mediators in CHF patients.
Method:
The randomized controlled trials investigating the effectiveness of XMLI treatment for CHF were retrieved from eight databases up until 31 December 2023. To evaluate the methodological quality of included studies, the Cochrane bias risk tool was employed. Furthermore, statistical analysis, sensitivity analysis, and publication bias assessment were conducted using Stata 17.0 software.
Result:
Compared with conventional treatment (CT), the combination therapy of XMLI and CT significantly improved LVR and reduced inflammatory mediators, mainly manifested by an increase in LVEF (MD = 6.40, 95% CI: 5.25 to 7.55, p = 0.000), a decrease in LVEDD (MD = -4.63, 95% CI: -5.69 to -3.57, p = 0.000) and LVESD (MD = -4.00, 95% CI: -5.50 to -2.50, p = 0.000), as well as a decrease in TNF-α (MD = -7.93, 95% CI: -9.86 to -6.00, p = 0.000), IL-6 (MD = -5.25, 95% CI: -6.59 to -3.92, p = 0.000), IL-18 (MD = -36.07, 95% CI: -46.76 to -25.38, p = 0.000), CRP (MD = -4.41, 95% CI: -6.40 to -2.42, p = 0.000), hs-CRP (MD = -4.90, 95% CI: -5.71 to -4.08, p = 0.000), and an increase in IL-10 (MD = 20.19, 95% CI: 10.42 to 29.97, p = 0.000). In addition, the combination therapy showed enhanced clinical efficacy (OR = 4.08, 95% CI: 3.10 to 5.37, p = 0.000), decreased expression levels of BNP (MD = -138.48, 95% CI: -155.48 to -121.48, p = 0.000), and NT-pro BNP (MD = -315.63, 95% CI: -359.25 to -272.00, p = 0.000), and increased the 6-MWD (MD = 71.02, 95% CI: 57.23 to 84.81, p = 0.000). It is noteworthy that the combination therapy did not lead to an increase in the incidence of adverse reactions (OR = 1.01, 95% CI: 0.68 to 1.50, p = 0.97).
Conclusion:
This systematic review and meta-analysis demonstrated the superiority of combining XMLI and CT therapies over CT alone in improving LVR and reducing inflammatory mediators in patients with CHF. Importantly, this combination therapy does not increase adverse reactions. However, it is crucial to exercise caution while interpreting the survey results due to the limited quality of the included studies.
Abstract:
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=492715, Identifier CRD42023492715.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
